TNFSF11 and breast cancer: A clinical trial found that using denosumab, a human monoclonal antibody targeting the RANKL, could reduce fractures and increase the prognosis of BC patients who are postmenopausal hormone receptor-positive and taking aromatase inhibitors 126.